BiotechTube

SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematopoietic and Lymphatic System Neoplasm

Conditions

Hematopoietic and Lymphatic System Neoplasm

Trial Timeline

Sep 1, 2026 → Jan 1, 2029

NCT ID
NCT07390968

About SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran

SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran is a phase 2 stage product being developed by Arcturus Therapeutics for Hematopoietic and Lymphatic System Neoplasm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07390968. Target conditions include Hematopoietic and Lymphatic System Neoplasm.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07390968Phase 2Recruiting

Competing Products

20 competing products in Hematopoietic and Lymphatic System Neoplasm

See all competitors
ProductCompanyStageHype Score
ASP0113Astellas PharmaPhase 2
52
Itacitinib + CorticosteroidJohnson & JohnsonPhase 2
52
Imipenem/Cilastatin/Relebactam + Cefepime + Meropenem + Piperacillin-Tazobactam + Vancomycin + Daptomycin + LinezolidMerckPhase 2
52
caspofungin + liposomal amphotericin BMerckPhase 2
52
Efprezimod alfa + Placebo + Methotrexate + TacrolimusMerckPhase 3
77
Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide + UprosertibNovartisPhase 1/2
41
ICL670NovartisApproved
85
Blinatumomab + Dexamethasone + Ibrutinib + NivolumabAmgenPhase 2
51
DenosumabAmgenPhase 2
51
RemdesivirGilead SciencesPhase 2
51
Inotuzumab Ozogamicin + Vincristine Sulfate LiposomePfizerPhase 1/2
40
SAR302503Bristol Myers SquibbPhase 2
51
SAR302503 + PlaceboBristol Myers SquibbPhase 3
76
SAR302503Bristol Myers SquibbPhase 2
51
SAR302503Bristol Myers SquibbPhase 2
51
NarsoplimabOmeros CorporationPre-clinical
18
Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 PlaceboSeres TherapeuticsPhase 1
25
BL-8040 + PlaceboBioLineRxPhase 1
25
Recombinant Interferon Alfa-2b + RintatolimodAIM ImmunoTechPhase 1/2
33
human lactoferrin peptide 1-11AM-PharmaPhase 1/2
33

Other Products from Arcturus Therapeutics

ARCT-2303 + Influenza vaccine + Influenza vaccine, adjuvantedPhase 3
69
ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine + Astra Zeneca COVID-19 vaccinePhase 2/3
57
ARCT-032Phase 2
44
ARCT-810Phase 2
44
ARCT-021 single dose priming + ARCT-021 two lower dose priming + ARCT-021 two higher dose priming + Placebo (two doses), priming + Randomized booster + Placebo boosterPhase 2
44